NCT04960657View on ClinicalTrials.gov

The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

March 19, 2021

Study Completion Date

March 19, 2021

Conditions
MigraineHeadachePain
Interventions
DRUG

glibenclamide

Oral administration of glibenclamide/placebo. To investigate the role of PACAP38 on cranial arteries in healthy volunteers after glibenclamide/placebo administration .

DRUG

PACAP38

PACAP38 infusion

Trial Locations (1)

2600

Danish Headache Center, Copenhagen

All Listed Sponsors
lead

Danish Headache Center

OTHER

NCT04960657 - The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers | Biotech Hunter | Biotech Hunter